An interventional study of Synbiotic Dual Cap® Intervention in Gastrointestinal Discomfort, Nausea and Bloating, sponsored by Epetome. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Epetome · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 292 studies in Nausea with a site in United States — 31 open to participants now, 34 under way, 8 of them phase 3. Nausea · United States.
Among the 292 studies in Nausea with a site in United States, this one is the 172nd largest by planned enrollment of the 262 interventional ones that give a count, is one of 9 that started in 2026, is one of 103 with no phase, reaches primary completion later than 12 of the 33 other live ones, and was the 291st registered.
644 studies on the registry are indexed under Nausea; 85 are open to participants now.
Browse Nausea studies →31 of the 292 studies in Nausea with a site in United States are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States
Ages 18–65 · Healthy volunteers
University of Southern California · Sites in United States
Ages 18–49 · Women only · Healthy volunteers
Vanda Pharmaceuticals · Sites in United States
Ages 18–65 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18+ · Women only
Eli Lilly and Company · Sites in United States, Australia, China and 7 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Nausea studies recruiting now, 22 (42%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
292 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 62 · Phase 3 49 · Phase 4 38
First in 1999; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 96 across 544 interventional studies indexed under Nausea.
Median enrollment 86 across the 262 interventional studies, 106 across the 25 observational. Of the 227 that completed or were terminated, 118 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 292 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Epetome as lead sponsor.
Epetome has 1 study filed under Nausea — fewer than ten, so there is no comparison to draw.
15 of the studies in Nausea with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07446439Phase 3Vanda PharmaceuticalsA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | 2026-12-01 |
| NCT06382012Phase 3Montefiore Medical CenterAntiemetic Fosaprepitant To Remedy Nausea and Vomiting | 2027-03 |
| NCT05418244Phase 3State University of New York at BuffaloInhaled Isopropyl Alcohol for Treatment of Nausea | 2027-06-30 |
| NCT06588413Phase 3Augusta UniversityOlanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan | 2027-10 |
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 292 studies in Nausea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.
Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Synbiotic Dual Cap® Intervention
Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication.
Change in Overall Gastrointestinal Comfort
Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires
Time frame: Baseline to Week 12
Change in Bowel Regularity
Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires
Time frame: Baseline to Week 12
Change in Bloating
Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires
Time frame: Baseline to Week 12
Change in Constipation
Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires
Time frame: Baseline to Week 12
Change in Diarrhea
Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires
Time frame: Baseline to Week 12
Change in Nausea
Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires
Time frame: Baseline to Week 12
Change in Post-Meal Fullness Comfort
Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires
Time frame: Baseline to Week 12
Participant Perception of Effect on Overall Gastrointestinal Comfort
Participants' self-reported perception of the product's tolerability and effect on overall gastrointestinal comfort, assessed using questionnaires
Time frame: Week 4, Week 8, and Week 12
Participant Perception of Effect on Bowel Regularity
Participants' self-reported perception of the product's tolerability and effect on bowel regularity, assessed using questionnaires
Time frame: Week 4, Week 8, and Week 12
Participant Perception of Effect on Bloating
Participants' self-reported perception of the product's tolerability and effect on bloating, assessed using questionnaires
Time frame: Week 4, Week 8, and Week 12
Participant Perception of Effect on Constipation
Participants' self-reported perception of the product's tolerability and effect on constipation, assessed using questionnaires
Time frame: Week 4, Week 8, and Week 12
Participant Perception of Effect on Diarrhea
Participants' self-reported perception of the product's tolerability and effect on diarrhea, assessed using questionnaires
Time frame: Week 4, Week 8, and Week 12
Participant Perception of Effect on Nausea
Participants' self-reported perception of the product's tolerability and effect on nausea, assessed using questionnaires
Time frame: Week 4, Week 8, and Week 12
Participant Perception of Effect on Post-Meal Fullness Comfort
Participants' self-reported perception of the product's tolerability and effect on post-meal fullness comfort, assessed using questionnaires
Time frame: Week 4, Week 8, and Week 12
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
Of 126 interventional studies with no phase under Nausea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.